Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Neuropharmacology. 2013 Apr 12;71:191–203. doi: 10.1016/j.neuropharm.2013.03.038

Fig. 8.

Fig. 8

Reduction in L-dopa-induced AIMs with sazetidine. The treatment regimen with sazetidine is depicted in the upper panel. All rats were unilaterally lesioned with 6-OHDA, subsequently injected with L-dopa plus benserazide (8.0 mg/kg plus 15 mg/kg sc) for several wk, after which they were treated with sazetidine at the indicated doses (twice daily sc). The rats were assessed for axial, oral and forelimb AIMs as depicted in the timeline, with the total AIMs representing the sum of the three components. The daily time course of the total L-dopa-induced AIMs is depicted in the graphs at the right. Values are the mean ± S.E.M. of 9–10 rats per group. Significance of difference from vehicle: *p < 0.05.